Takeda Pharmaceutical (TAK) Interest & Investment Income (2017 - 2026)

Takeda Pharmaceutical has reported Interest & Investment Income for 10 years, with the latest figure at $154.4 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income fell 69.71% year-over-year to $154.4 million in Q2 2026; TTM through Jun 2026 was $2.1 billion, a 50.44% increase from a year earlier, with the FY2026 full-year figure at $1.3 billion, up 340.65% from the prior year.
• Interest & Investment Income was $154.4 million for Q2 2026 at Takeda Pharmaceutical, down from $470.6 million in the prior quarter.
• The five-year high for Interest & Investment Income was $113.4 billion in Q1 2022, with the low at $94.7 million in Q4 2023.
• Average Interest & Investment Income over 5 years is $12.5 billion, with a median of $302.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 25173.51% in 2022, then plunged 99.8% in 2024.
• Over 5 years, Interest & Investment Income stood at $295.0 million in 2022, then plunged by 67.9% to $94.7 million in 2023, then gained by 29.87% to $123.0 million in 2024, then slipped by 1.21% to $121.5 million in 2025, then advanced by 27.06% to $154.4 million in 2026.
• The last three Interest & Investment Income figures came in at $154.4 million (Q2 2026), $470.6 million (Q1 2026), and $121.5 million (Q4 2025), per Business Quant data.